{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.62","upperLimit":"52.97","value":"37.84"},{"groupId":"OG001","lowerLimit":"23.72","upperLimit":"54.74","value":"39.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Estimated 3-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Arm I (Low-dose Lenalidomide)"},{"description":"Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG001","title":"Arm II (High-dose Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"Only eligible patients are considered in the analysis of this outcome measure","reportingStatus":"POSTED","timeFrame":"Up to 3 years after study enrollment","title":"Event-free Survival [EFS]","type":"SECONDARY","unitOfMeasure":"Percent Probability"}